Company
London, OS
Every investor coverage indicates participated in a round University College London raised.
Companies University College London acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Professor Chris Denton | Professor of Experimental Rheumatology | Brandon Capital, Brandon BioCatalyst |
| Jesse Clark | Postdoctoral Researcher (former) | Blackbird Ventures |
| Dan Brett | Professor | RenewEconomy |
Stories naming University College London. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics reported encouraging Phase 2 results for its scleroderma drug FT011 at a US rheumatology meeting, with safety confirmed and a pivotal trial planned.
Australian biotech Certa Therapeutics reports Phase 2 scleroderma trial results for FT011 at a US rheumatology meeting, showing efficacy and safety, with a pivotal study planned.
Blackbird announces it led AI search startup Marqo's seed round, joined by January Capital, The Creator Fund and angel investors, having previously backed the company's pre-seed in May 2022.
Also TechCrunch Australia·Startup Daily·SmartCompany·SmartCompany·Startup Daily·SmartCompany